País: Reino Unido
Idioma: inglés
Fuente: MHRA (Medicines & Healthcare Products Regulatory Agency)
Levothyroxine sodium anhydrous
Advanz Pharma
H03AA01
Levothyroxine sodium anhydrous
10microgram/1ml
Oral solution
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 06020100; GTIN: 5021691019770
WHAT IS IN THIS LEAFLET 1. What Eltroxin Oral Solution is and what it is used for 2. What you need to know before you take Eltroxin Oral Solution 3. How to take Eltroxin Oral Solution 4. Possible side effects 5. How to store Eltroxin Oral Solution 6. Contents of the pack and other information 1. WHAT ELTROXIN ORAL SOLUTION IS AND WHAT IT IS USED FOR Eltroxin Oral Solution contains levothyroxine which is used to treat hypothyroidism, a condition in which the thyroid gland is underactive and so does not make enough thyroxine for the body's needs. Eltroxin Oral Solution is also used to treat thyroid ca ncer and diffuse non-toxic goitre or Hashimoto's thyroiditis, conditions in which the thyroid gland becomes enlarged causing a swelling in the front of the neck. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ELTROXIN ORAL SOLUTION DO NOT TAKE ELTROXIN ORAL SOLUTION: If you are allergic to levothyroxine or any of the other ingredients of this medicine (listed in section 6) If you suffer from adrenal insufficiency and you do not have adequate corticosteroid cover If you have a heart attack (acute myocardial infarction), inflammation of the heart muscle (acute myocarditis) or inflammation of the sac surrounding the heart (acute pancarditis) If you are pregnant do not take this medicine in combination with medicines to treat hyperthyroidism (see the section on Pregnancy and breast-feeding). WARNINGS AND PRECAUTIONS Talk to your doctor before taking Eltroxin Oral solution: If you have heart disease, problems with your circulation or high blood pressure If you are suffering from an overactive thyroid gland (hyperthyroidism), an underactive adrenal g land, diabetes, or have had an underactive thyroid gland for some time. OTHER MEDICINES AND ELTROXIN ORAL SOLUTION Please tell your doctor or pharmacist if you are taking, have recently taken or might use any other medicines. Levothyroxine can interfere with the action of some other drugs and some drugs can have an effect on Levothyroxine. In particular tell your doctor or pharmacist Leer el documento completo
OBJECT 1 ELTROXIN 50MICROGRAMS PER 5ML ORAL SOLUTION Summary of Product Characteristics Updated 30-Aug-2013 | Concordia International - formerly AMCo 1. Name of the medicinal product Eltroxin 50micrograms per 5ml Oral Solution 2. Qualitative and quantitative composition Each 5ml of oral solution contains 50micrograms Levothyroxine Sodium Excipients with known effect: Sodium methyl hydroxybenzoate (E219): 9mg per 5ml dose. Glycerol: 3,780mg per 5ml dose. For a full list of excipients, see section 6.1. 3. Pharmaceutical form Oral Solution Clear colourless liquid. 4. Clinical particulars 4.1 Therapeutic indications Eltroxin Oral Solution is indicated for: i) hypothyroidism (congenital or acquired) ii) diffuse non toxic goitre iii) goitre associated with Hashimoto's thyroiditis iv) Suppression therapy in thyroid carcinoma 4.2 Posology and method of administration The treatment of any thyroid disorder should be determined on an individual basis, taking account of clinical response, biochemical tests and regular monitoring. The individual daily dose should be determined on the basis of laboratory tests and clinical examinations. As a number of patients show elevated concentrations of T4 and fT4, basal serum concentration of thyroid-stimulating hormone provides a more reliable basis for following treatment course. Patients switching from the oral solution to the tablet form or from the tablet form to the oral solution should be monitored closely. Levothyroxine is best taken as a single dose on an empty stomach, usually before breakfast. Hypothyroidism (congenital or acquired) Adults, children over 12 years Initial dose: 50 - 100 micrograms daily before breakfast. Usual maintenance dose: 100 - 200 micrograms daily. The initial dose is adjusted by 25 to 50 microgram increments at 3 4 week intervals until clinical response and measurements of plasma thyroxine and thyroid stimulating hormone indicate that the thyroid deficiency is corrected and a maintenance dose established. Diffuse non toxic goitre or goitre associated Leer el documento completo